BACKGROUND: Data on outcomes of antiretroviral treatment (ART) programs in rural sub-Saharan African are scarce. We describe early losses and long-term outcomes in 6 rural programs in Southern Africa with limited access to viral load monitoring and second-line ART. METHODS: Patients aged ≥16 years starting ART in 2 programs each in Zimbabwe, Mozambique, and Lesotho were included. We evaluated risk factors for no follow-up after starting ART and mortality and loss to follow-up (LTFU) over 3 years of ART, using logistic regression and competing risk models. Odds ratios and subdistribution hazard ratios, adjusted for gender, age category, CD4 category, and World Health Organization stage at start of ART are reported. RESULTS: Among 7725 patients, 449 (5.8%) did not return after initiation of ART. During 9575 person-years, 698 (9.6%) of those with at least 1 follow-up visit died, and 1319 (18.1%) were LTFU. At 3 years, the cumulative incidence of death and LTFU were 12.5% (11.5%-13.5%) and 25.4% (24.0%-26.9%), respectively, with important differences between countries as follows: in Zimbabwe 75.1% (72.8%-77.3%) were alive and on ART at 3 years compared with 55.4% (52.8%-58.0%) in Lesotho and 51.6% (48.0%-55.2%) in Mozambique. In all settings, young age and male gender predicted LTFU, whereas advanced clinical stage and low baseline CD4 counts predicted death. CONCLUSIONS: In African ART programs with limited access to second-line treatment, mortality, and LTFU are high in the first 3 years of ART. Low retention in care is a major threat to the sustainability of ART delivery in Southern Africa, particularly in rural sites.
BACKGROUND: Data on outcomes of antiretroviral treatment (ART) programs in rural sub-Saharan African are scarce. We describe early losses and long-term outcomes in 6 rural programs in Southern Africa with limited access to viral load monitoring and second-line ART. METHODS:Patients aged ≥16 years starting ART in 2 programs each in Zimbabwe, Mozambique, and Lesotho were included. We evaluated risk factors for no follow-up after starting ART and mortality and loss to follow-up (LTFU) over 3 years of ART, using logistic regression and competing risk models. Odds ratios and subdistribution hazard ratios, adjusted for gender, age category, CD4 category, and World Health Organization stage at start of ART are reported. RESULTS: Among 7725 patients, 449 (5.8%) did not return after initiation of ART. During 9575 person-years, 698 (9.6%) of those with at least 1 follow-up visit died, and 1319 (18.1%) were LTFU. At 3 years, the cumulative incidence of death and LTFU were 12.5% (11.5%-13.5%) and 25.4% (24.0%-26.9%), respectively, with important differences between countries as follows: in Zimbabwe 75.1% (72.8%-77.3%) were alive and on ART at 3 years compared with 55.4% (52.8%-58.0%) in Lesotho and 51.6% (48.0%-55.2%) in Mozambique. In all settings, young age and male gender predicted LTFU, whereas advanced clinical stage and low baseline CD4 counts predicted death. CONCLUSIONS: In African ART programs with limited access to second-line treatment, mortality, and LTFU are high in the first 3 years of ART. Low retention in care is a major threat to the sustainability of ART delivery in Southern Africa, particularly in rural sites.
Authors: Didier K Ekouevi; Eric Balestre; Franck-Olivier Ba-Gomis; Serge Paul Eholie; Moussa Maiga; Clarisse Amani-Bosse; Albert Minga; Eugène Messou; Papa Salif Sow; Charlotte Lewden; Hamar Allassane Traoré; Emmanuel Bissagnene; François Dabis Journal: Trop Med Int Health Date: 2010-06 Impact factor: 2.622
Authors: Margaret May; Andrew Boulle; Sam Phiri; Eugene Messou; Landon Myer; Robin Wood; Olivia Keiser; Jonathan A C Sterne; Francois Dabis; Matthias Egger Journal: Lancet Date: 2010-07-15 Impact factor: 79.321
Authors: Andrew N Phillips; Deenan Pillay; Alec H Miners; Diane E Bennett; Charles F Gilks; Jens D Lundgren Journal: Lancet Date: 2008-04-26 Impact factor: 79.321
Authors: Matthias Egger; Ben D Spycher; John Sidle; Ralf Weigel; Elvin H Geng; Matthew P Fox; Patrick MacPhail; Gilles van Cutsem; Eugène Messou; Robin Wood; Denis Nash; Margaret Pascoe; Diana Dickinson; Jean-François Etard; James A McIntyre; Martin W G Brinkhof Journal: PLoS Med Date: 2011-01-18 Impact factor: 11.069
Authors: Tom Decroo; Isabella Panunzi; Carla das Dores; Fernando Maldonado; Marc Biot; Nathan Ford; Kathryn Chu Journal: J Int AIDS Soc Date: 2009-05-06 Impact factor: 5.396
Authors: Bea Vuylsteke; Gisèle Semdé; Andrew F Auld; Jennifer Sabatier; Joseph Kouakou; Virginie Ettiègne-Traoré; Anne Buvé; Marie Laga Journal: J Acquir Immune Defic Syndr Date: 2015-03-01 Impact factor: 3.731
Authors: Kevin P Fiori; Hayley M Belli; Molly E Lauria; Lisa R Hirschhorn; Jennifer Schechter; Emily Hansman; Nandita Rajshekhar; Venance Katin; Sesso Gbeleou; Meskerem Grunitsky-Bekele; Vincent Palokinam Pitche Journal: AIDS Care Date: 2019-06-06
Authors: Nanina Anderegg; Jonas Hector; Laura F Jefferys; Juan Burgos-Soto; Michael A Hobbins; Jochen Ehmer; Lukas Meier; Marloes H Maathuis; Matthias Egger Journal: J Clin Epidemiol Date: 2020-08-20 Impact factor: 6.437
Authors: Edith Apondi; John M Humphrey; Edwin Sang; Ann Mwangi; Alfred Keter; Beverly S Musick; Fred K Nalugoda; John Ssali; Elizabeth Bukusi; Constantin T Yiannoutsos; Kara Wools-Kaloustian; Samuel Ayaya Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.731
Authors: Robert Gross; Scarlett L Bellamy; Bakgaki Ratshaa; Xiaoyan Han; Andrew P Steenhoff; Mosepele Mosepele; Gregory P Bisson Journal: Addiction Date: 2016-09-07 Impact factor: 6.526